The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1561
December 3, 2018
View Complete Issue         Table of Contents 2019 
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
December 3, 2018 (Issue: 1561)
The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Baloxavir Marboxil (Xofluza) for Treatment of Influenza
Article code: 1561a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.